Aileron Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Rein Therapeutics

15/04/2024 23:10

* Aileron Therapeutics Inc  ALRN.OQ  reported a quarterly
adjusted
loss of $1.54​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of $-1.02.  The lone analyst forecast for the quarter was
for a loss of 16 cents per share. 
    * Reported revenue was zero​. 
    * Aileron Therapeutics Inc's reported EPS for the quarter
was a
loss of $1.54​.
    * The company reported a quarterly loss of $7.34 million.
    * Aileron Therapeutics Inc shares had fallen by 7.4% this
quarter and gained 101.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Aileron
Therapeutics Inc is $9.00 
This summary was machine generated from LSEG data April 15 at
10:09 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.16          -1.54          Missed
                                  -0.40          
                                  -0.39          
 Mar. 31 2023      -0.86          -1.05          Missed